GUADALAJARA, Mexico, June 5, 2026 /PRNewswire-HISPANIC PR WIRE/ -- Jalisco, Mexico has firmly established itself on the global culinary stage as the official host...
For approved assets, click hereLAS VEGAS, June 4, 2026 /PRNewswire/ -- Formula 1® will continue racing in Las Vegas, the Sports and Entertainment Capital...
Toronto's Inner Harbour welcomes a pilot marine initiative, connecting select destinations by water TORONTO, June 4, 2026 /CNW/ - Toronto's waterfront marked an exciting...
Saint Herblain (France), August 18, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that Health Canada has granted marketing authorization for its single-dose vaccine, IXCHIQ®, for the prevention of disease caused by the chikungunya virus in individuals aged 12 years and older. This announcement adds to the adult marketing authorization already received in Canada1 and complements the adolescent label extension received in Europe in April 20252.